Elsevier

Clinical Therapeutics

Volume 27, Issue 1, January 2005, Pages 64-77
Clinical Therapeutics

Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo*

https://doi.org/10.1016/j.clinthera.2005.01.002Get rights and content

Abstract

Background:

Lumiracoxib is a cyclooxygenase-2-selectiveinhibitor developed for the treatment of osteoarthritis (OA), rheumatoid arthritis, and acute pain.

Objectives:

This study assessed the efficacy and tolerability of lumiracoxib 100 mg QD compared with celecoxib and placebo in patients with OA of the knee.

Methods:

In this 13-week, double-blind, double-dummy,placebo-controlled, parallel-group study, patients with primary OA of the knee and pain intensity in the target knee a40 mm on a 100-mm visual analog scale after a 3- to 7-day washout of nonsteroidal anti-inflammatory drugs were randomized to receive lumiracoxib 100 mg QD, lumiracoxib 100 mg QD with a loading dose of lumiracoxib 200 mg QD for the first 2 weeks, celecoxib 200 mg QD, or placebo. Three primary efficacy variables were assessed at the end of the study: pain intensity in the target knee, the patient's global assessment of disease activity, and functional status (Western Ontario and McMaster Universities Osteoarthritis Index total score). In addition, the treatment response was assessed using the Outcome Measures in Clinical Trials-Osteoarthritis Research Society International (OMERACT OARSI) criteria. The safety profile and tolerability of all treatments were also examined.

Results:

The study enrolled 1551 patients (primarily white; 62% female; mean age, 60.5 years): 391 were randomized to receive lumiracoxib 100 mg QD, 385 lumiracoxib 100 mg QD with a loading dose, 393 celecoxib 200 mg QD, and 382 placebo. Treatment groups were closely balanced at baseline with respect to demographic and disease characteristics. Lumiracoxib was superior to placebo (P < 0.001) and similar to celecoxib on all primary efficacy variables. Reductions in pain intensity in the target knee were similar in the 2 lumiracoxib groups at week 13 (estimated least square mean difference vs placebo: −6.7 and −8.1 mm for lumiracoxib 100 mg QD and lumiracoxib 100 mg QD with loading dose, respectively; both, P < 0.001); with celecoxib, the estimated least square mean difference was −5.7 mm (P < 0.001). Significant differences compared with placebo were seen in all variables starting at week 2 for all active treatments (all, P < 0.001). No significant differences were seen between the lumiracoxib groups at any time point. Based on OMERACT OARSI criteria, all active treatments were superior to placebo (all, P < 0.001). Lumiracoxib and celecoxib were well tolerated, with an incidence of adverse events similar to that with placebo (64.7% lumiracoxib 100 mg QD, 67.0% lumiracoxib 100 mg QD with loading dose, 58.8% celecoxib, 58.4% placebo).

Conclusion:

In this population of patients with OA of the knee, lumiracoxib 100 mg QD was of similar efficacy to celecoxib 200 mg QD and had similar tolerability to placebo.

References (38)

  • Hernandez-DiazS. et al.

    Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs

    Am J Med

    (2001)
  • WolfeM.M. et al.

    Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs

    N Engl J Med

    (1999)
  • MooreR.A.

    The hidden costs of arthritis treatment and the cost of new therapy—the burden of non-steroidal antiinflammatory drug gastropathy

    Rheumatology (Oxford)

    (2002)
  • McKennaF. et al.

    Celecoxib versus diclofenac in the management of osteoarthritis of the knee

    Scand J Rheumatol

    (2001)
  • DeeksJ.J. et al.

    Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials

    BMJ

    (2002)
  • KivitzA.J. et al.

    Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: A randomized controlled trial

    J Am Geriatr Soc

    (2004)
  • BombardierC. et al.

    Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis

    N Engl J Med

    (2000)
  • WarnerT.D. et al.

    Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic

    FASEB J

    (2004)
  • ScottG. et al.

    Dose escalation study to assess the safety, tolerability, pharmaco kinetics and pharmacodynamics of COX189 in healthy subjects

    Ann Rheum Dis

    (2002)
  • Cited by (61)

    • Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: A meta-analysis of randomized placebo-controlled trials

      2010, Osteoarthritis and Cartilage
      Citation Excerpt :

      The results of the article selection process are reported in Fig. 1. From the 343 articles identified, 33 articles were included14–46. Flare design was used in 27/33 (82%) studies.

    • Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?

      2021, Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
    View all citing articles on Scopus
    *

    Data from this study were presented as a poster at the 9th World Congress on Osteoarthritis, December 2-5, 2004, Chicago, Illinois.

    View full text